To Be or Not to Be that is the Question?
No it is Not!
The Question is Does Getting Rid of the B cells
Inhibit Progressive MS Independent of Getting Rid of Active Inflammation
so
To (Deplete) B or Not to (Deplete) B that is the Question
(for PPMS)
Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial
Maybe ProfG can post the Answer Apres-ski as I am sure he knows as one of the collaborators
Alternatively Why Not Tweet the Answer.
The Talk is Today.
I suspect the answer is going to be that it does not matter,
but that would rewrite the history of anti-inflammatories in PPMS
including the rituximab in PPMS conclusion.
We will See.